Table 2 Treatment combinations in the 133 patients analysed

Number of treatment combinations, n (%)

 1

115 (86.0)

 2

12 (9.0)

 3

5 (3.8)

 5

1 (0.8)

Number of treatment combinations

(N = 159)

Targeted agent combined with lanreotide, n (%)

 Everolimus

73 (45.9)

 Sunitinib

61 (38.4)

Treatment discontinuation, n (%)^a

84 (52.8)

 Everolimus

n = 73

  All discontinuations

39 (53.4)

   Disease progression

23 (31.5)

   Adverse event

10 (13.7)

   Other

6 (8.2)

  Ongoing

34 (46.6)

 Sunitinib

n = 61

  All discontinuations

27 (44.3)

   Disease progression

15 (24.6)

   Adverse event

10 (16.4)

   Other

2 (3.3)

  Ongoing

34 (55.7)